Prostate Cancer Therapeutics - A Global Market Perspective

1.METHODOLOGY
Study Reliability and Reporting Limitations
Disclaimers
Quantitative Techniques & Reporting Level
2.GLOBAL MARKET OVERVIEW AND OUTLOOK
A Prelude…
New Products to Bolster Sales of Prostate Cancer Therapeutics
Key Prostate Cancer Drugs & Companies
Hormone Therapies to Dominate Global Prostate Cancer Therapeutics Market
Select Prostate Cancer Hormonal Therapy Drugs with Year of FDA Approval
Targeted Therapy - The New Frontier of Cancer Treatment
Radiotherapy - Gaining Prominence
Innovations in Drug Delivery: A Key Factor in Product Differentiation
New Therapies Appear Over the Horizon
New Generation Prostate Cancer Drugs and Their Area of Use
Small Cap Companies: A Target of Private Capital Financing
Drugs (that are both available and under pipeline) Developed by the Three Small-Cap Companies
Minimally Invasive Devices Likely to Get Good Reception in Emerging Markets
Awareness Drives European Prostate Cancer Therapeutics Market
Growth Drivers
Rise in Prostate Cancer Incidences & Access to Modern Therapeutics Foster Growth
Demographics & Lifestyles Raise the Risk of Prostate Cancer
Select General Risk Factors and their Relative Risk Rate in Prostate Cancer
Unmet Needs Leave Scope for Further Research and Development
Supportive Cancer Drugs Contribute to Growth
Select FDA Approved Drugs for Palliative Treatment of Advanced Prostate Cancer
Improved Screening, Diagnosis & Patient Survival Rates Trigger Growth
Molecular Imaging of Cancer: Critical in Improving Patient Outcomes
Growth Restraints
Limited Tumor Specificity and Toxicity
Complicated Treatment Protocols: A Major Stumbling Block in Patient Compliance.
Multiple Drug Resistance
Stringent Regulations Delay Market Approval
Ongoing Clinical Trials in Hormone Refractory Prostate Cancer
Challenges Encountered in Clinical Trials
Notable Prostate Cancer Drug Failures in Phase III Development
High Development Costs Retracts Manufacturers in Developing Countries
3.CLINICAL TRIALS
Drugs in Pipeline
Select Prostate Cancer Drugs/ Compounds in Pipeline
Select Prostate Cancer Drugs Under Phase II/III Trials by Leading Companies
Drugs in Pre-Clinical Stage
Select Prostate Cancer Drugs/ Compounds in Pre-Clinical Stage
Commercially Available Drugs
Select Prostate Cancer Drugs (Commercially Available) by Leading Companies
4.PRODUCT FACTS
Hormonal Therapy
Radiation Therapy
Chemotherapy
Surgical Procedures
Other Treatment Options
5.CORPORATE DEVELOPMENTS
Sanofi-Aventis Secures Approval of Japanese Health Ministry for Taxotere® Injection
Schering-Plough Terminates Collaboration with Novacea
Takeda Terminates JV Deal, Merges its Subsidiaries
Aureon Laboratories and Pfizer Announce Research Partnership
Celera Enters into Licensing Agreement with Merck
Celera Announces Demerger from Applera Corporation
GPC Biotech and Celgene Terminate Agreement for Satraplatin
EUSA Acquires Cytogen Corporation
Eisai Acquires MGI Pharma
BN ImmunoTherapeutics Enters into a Scientific Partnership with NCI
Morphotek® Enters into Licensing Agreement with NCI
ValiRx Acquires Exclusive Evaluation License from CRT for New Prostate Cancer Compound
Cell Genesys Forms Global Alliance with Takeda on GVAX Immunotherapy Development for Prostate Cancer
Sirnaomics Extends Partnership with GRL to Develop Multi-Targeted RNAi Therapeutic Products
Aureon and Pfizer to Collaborate on New Stage of Research Project
CancerPartners UK Collaborates with Spire Healthcare
Cougar Biotech Enters into an Agreement with US FDA
Scottish Scientists Receives Contract from Cancer Research UK
Speciality European Pharma Introduces Plenaxis
Actavis Unveils Bicalutamide Tablets for Prostate Cancer in the European Markets
Debiopharm Unveils Results of Phase III Study of Trelstar in Prostate Cancer Treatment
Algeta to Start Clinical Study of Alpharadin in HRPC
Ferring Receives FDA Approval for Degarelix in Prostate Cancer
Isis and OncoGenex Reveals Positive results of OGX-011 Molecule in HRPC
Antisoma Completes Phase 2 Study of ASA404 in Prostate Cancer
Cougar Conducts Phase I/II Clinical Trials on CB7630 in Patients with Prostate Cancer
ValiRx Collaborates with University of Surrey on Prostate Cancer Diagnostics
ValiRx Subsidiary Extends Collaboration with Cancer Research Technology
MacroArray Partners with Abbott on PCADM-1 Test for Prostate Cancer
Novacea Enters into Agreement with Schering-Plough
Bayer to Stop Sale of Viadur – A Drug for Prostate Cancer
Sagemark Embarks on Radiation Therapy Venture
RTS Concludes Californian Radiation Therapy Center Acquisition
Radiation Therapy Takes Over a North Carolina Treatment Center
DRAXIMAGE and Med Discovery Enter into Research Collaboration
Core Oncology Completes Acquisition of Coloplast’s Brachytherapy Business
Novacea Licenses Asenstar Prostate Cancer Drug to Schering-Plough
Bentley Receives Approval for Generic Version of Casodex
GSK Acquires Praecis Pharmaceuticals
Samaritan Acquires Metastatin Pharma
Champions Biotechnology Acquires Patent Rights for Potential Cancer Treatments
GPC Biotech Submits NDA for Treatment of Prostate Cancer
Artemis to Introduce IGRT
Immunomedics Introduces Immunotoxin for Treatment of Prostate and Lung Cancer
Barr Unveils Generic Version of Proscar® Tablets
IRX Therapeutics to Develop Vaccine for Prostate Cancer
Actavis Introduces New Generic Drugs in Europe
Ambrilia Unveils Results of PCK3145 in Patients with Metastatic Prostate Cancer
Peregrine Pharmaceuticals Reveals Pre-Clinical Data on Bavituximab in Prostate Cancer
Cell Genesys Reveals Data of GVAX Immunotherapy for Treatment of Prostate Cancer
Bioponic Phytoceuticals Unveils Pre-Clinical Data on Curecumin™ for Prostate Cancer
New Study Reveals Cough Medicine – Noscapine to be Effective in Prostate Cancer
Fosamax® Found Effective in Preventing Bone Loss in Prostate Cancer Patients
Genta Unveils Results of Phase II Clinical Trial of Genasense® in Prostate Cancer
Cell Therapeutics Reveals Phase 2 Clinical Trial Results of XYOTAX™ in Androgen Independent Prostate Cancer Patients
Sanofi-Aventis’ Taxotere® Enhances Survival in Metastatic Prostate Cancer Patients
NCI Initiates Phase 2 Clinical Trial of Cytogen’s QUADRAMET for HRPC
Cleveland BioLabs to Initiate Phase II Clinical Trial for Curaxin in HRPC
6.MAJOR PLAYERS
Abbott Laboratories (USA)
Æterna Zentaris Inc.
ALZA Corporation (USA)
Amgen Inc. (USA)
AstraZeneca PLC (UK)
Medimmune, LLC (USA)
Bristol-Myers Squibb Company (USA)
Cell Genesys Inc. (USA)
Dendreon Corporation (USA)
EUSA Pharma, (USA) Inc. (USA)
F. Hoffmann-La Roche Ltd. (Switzerland)
Genentech Inc. (USA)
GlaxoSmithKline Plc (UK)
Immunomedics, Inc. (USA)
Novartis AG (Switzerland)
OSI Pharmaceuticals, Inc. (USA)
Paladin Labs Inc. (Canada)
Pfizer Inc. (USA)
Progenics Pharmaceuticals, Inc. (USA)
Sanofi-Aventis SA (France)
Spectrum Pharmaceuticals, Inc. (USA)
Takeda Pharmaceutical Company Limited (Japan)
7.GLOBAL MARKET ANALYTICS
8.THE UNITED STATES
Overview
A Surging US Prostate Cancer Therapeutics Market
Cost of Cancer Drugs – A Major Concern in the US
Market Accelerators
Market Challenges
Market Inhibitors
Outlook
9.EUROPE
a.France
b.Germany
c.Italy
d.The United Kingdom
e.Spain
f.Rest of Europe
10.REST OF WORLD
A Peek into Canadian Market
Ambrilia Unveils Results of PCK3145 in Patients with Metastatic Prostate Cancer
Ambrilia Reveals Results of PSP-94 Immunoassay Study for Cancer Therapy
A Glance into Other Select Markets
Minimally Invasive Devices Likely to Get Good Reception in Emerging Markets
Cancer Market in Asia
Australia
India
Japan
Malaysia
Cancer Market in Latin America
Brazil
Mexico
Argentina
Exhibits
Table 1: Global Prostate Cancer Therapeutics Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 2: Percentage Breakdown of Global Prostate Cancer Therapeutics Market by Region for the Years 2009 &
Table 3: Sales of FDA Approved Prostate Cancer Hormonal Therapy Drugs in the US – 2007 (in US$ Million)
Table 4: Prostate Cancer Therapeutics Market in the US: 2007-2015 (Sales in US$ Million)
Table 5: Breakdown of New Cases of Prostate Cancer Diagnosed in Europe by Region/Country– 2008 (In ‘000)
Table 6: Prostate Cancer Therapeutics Market by Region in Europe: 2007-2015 (Sales in US$ Million)
Table 7: Percentage Breakdown of Prostate Cancer Therapeutics Market by Region in Europe for the Years 2009 &
Table 8: Prostate Cancer Therapeutics Market in France: 2007-2015 (Sales in US$ Million)
Table 9: German Prostate Cancer Therapeutics Market: 2007-2015 (Sales in US$ Million)
Table 10: Italian Prostate Cancer Therapeutics Market in Italy: 2007-2015 (Sales in US$ Million)
Table 11: Prostate Cancer Therapeutics Market in the UK: 2007-2015 (Sales in US$ Million)
Table 12: Prostate Cancer Therapeutics Market in Spain: 2007-2015 (Sales in US$ Million)
Table 13: Prostate Cancer Therapeutics Market in Rest of Europe: 2007-2015 (Sales in US$ Million)
Table 14: Prostate Cancer Therapeutics Market in Rest of World: 2007-2015 (Sales in US$ Million)
Companies Profiled